Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4063390 | 0.99 | PDE4A (0.49) | PDE4AKCNH2RORCHTR3APTGS2 | |
| SCHEMBL4065600 | 0.89 | KCNH2 (0.52) | PDE4AKCNH2HTR3A | |
| SCHEMBL4058513 | 0.85 | KCNH2 (0.47) | PDE4AKCNH2RORCHTR3A | |
| SCHEMBL4059167 | 0.83 | PABPC1 (0.43) | PDE4AKCNH2HTR3A | |
| SCHEMBL4063711 | 0.82 | RORC (0.53) | PDE4AKCNH2RORCPTGS2PTGDR2 | |
| SCHEMBL4059266 | 0.81 | HTR3A (0.55) | PDE4AKCNH2RORCHTR3A | |
| SCHEMBL4062695 | 0.81 | PDE4A (0.54) | PDE4AKCNH2RORCPTGS2PTGDR2 | |
| SCHEMBL4061518 | 0.81 | PDE4A (0.41) | PDE4AKCNH2RORCHTR3A | |
| SCHEMBL4061505 | 0.81 | HTR3A (0.47) | PDE4AKCNH2RORCHTR3A | |
| SCHEMBL4062665 | 0.80 | PDE4A (0.52) | PDE4AKCNH2RORCPTGS2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641791-B1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | claimed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | claimed |
| EP-1641791-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| WO-2004111048-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | WO | claimed |
| EP-1641791-B1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1641791-B1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| EP-1641791-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004111048-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004111048-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | TNNI3, TNNT2, TNNC1 | PDE4A 842/4885KCNH2 52/4885RORC 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.